Program
Etoricoxib
Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.
Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.
Drug pageEtoricoxib: every studyMany companies study it; this page follows only the 34 they lead. All 71 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 230 open or running | phase 4since Aug 25, 2004 | Aug 25, 2004 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 61 open or running | phase 3since Jul 13, 2021 | Jul 13, 2021 | Dec 31, 2026phase 3 · NCT06863701 |
| Analgesic Solutionsits history only | 10 open or running | phase 4since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Jan 30, 2018 | Jan 30, 2018 | none ahead |
| Laboratorios Liomontits history only | 10 open or running | phase 3since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Mar 31, 2021 | Mar 31, 2021 | none ahead |
| X-pert Medits history only | 10 open or running | phase 1since Jan 5, 2011 | Jan 5, 2011 | none ahead |
Also a collaborator on its studies: EPIC Research CRO, PT Equilab International and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Laboratorios Silanes S.A. de C.V. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2021First study: phase 3 study in Back PainFirst studyNCT04968158 · 124 enrolled · Mexico
- Sep 6, 2022Phase 1 study in PainNCT05533073 · 42 enrolled · Mexico
- Jul 18, 2024Phase 3 study in Acute PainNCT06517823 · 190 enrolled · Mexico
- Mar 3, 20252 phase 3 studiesNCT06863701, NCT06863662
- Dec 28, 2025Phase 3 study in BursitisNCT07328022 · 89 enrolled · Mexico
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Arthritis, GoutyNCT06863701
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Meloxicamrule | Boehringer Ingelheim | phase 4 | 67 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 6 Laboratorios Silanes S.A. de C.V. leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07328022Bursitis · Mexico | 3 | Completed | Aug 20, 2025 | 89 |
| NCT06863701Arthritis, Gouty · Mexico | 3 | Recruiting | Dec 31, 2026 | 72 |
| NCT06863662Spasm · Mexico | 3 | Completed | Sep 26, 2025 | 136 |
| NCT06517823Acute Pain · Mexico | 3 | Completed | Oct 4, 2024 | 190 |
| NCT05533073Pain · Mexico | 1 | Completed | Sep 7, 2020 | 42 |
| NCT04968158Back Pain · Mexico | 3 | Completed | Mar 15, 2022 | 124 |
How it is read
Names in the registry
- “etoricoxib”, 7 entries
- “Etoricoxib”, 4 entries
- “MK0663, etoricoxib”, 3 entries
- “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
- “Etoricoxib 90 mg”, 2 entries
Codes read as this program: MK0663.
Conditions, from the studies’ own filings
- Osteoarthritis, 8 studies
- Pain, 5 studies
- Low Back Pain, 3 studies
- Acute Pain, 2 studies
- Dysmenorrhea, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.